The effects of topical everolimus and sunitinib on corneal neovascularization

References

• DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg 2011;37:588–598
   PubMed Web of Science ®Google Scholar
• Qazi Y, Wong G, Monson B, et al. Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull 2010;81:198–210
   PubMed Web of Science ®Google Scholar
• Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006;84:282–288
   PubMedGoogle Scholar
• Nowak JZ, Wiktorowska-Owczarek A. Neovascularization in ocular tissues: mechanisms and role of proangiogenic and antiangiogenic factors. Klin Oczna 2004;106:90–97
   PubMedGoogle Scholar
• Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557–563
   PubMedGoogle Scholar
• Chang JH, Garg NK, Lunde E, et al. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 2012;57:415–429
   PubMed Web of Science ®Google Scholar
• Benayoun Y, Casse G, Forte R, et al. Corneal neovascularization: epidemiological, physiopathological, and clinical features. J Fr Ophtalmol 2013;36:627–639
   PubMed Web of Science ®Google Scholar
• Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245–269
   PubMed Web of Science ®Google Scholar
• Rajappa M, Saxena P, Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem 2010;50:103–121
   PubMed Web of Science ®Google Scholar
• Mirabelli P, Peebo BB, Xeroudaki M, et al. Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model. Exp Eye Res 2014;125:118–127
   PubMed Web of Science ®Google Scholar
• Trikha S, Parikh S, Osmond C, et al. Long-term outcomes of Fine Needle Diathermy for established corneal neovascularisation. Brit J Ophthalmol 2014;98:454–458
   PubMed Web of Science ®Google Scholar
• Bucak YY, Erdurmus M, Terzi EH, et al. Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits. Graefes Arch Clin Exp Ophthalmol 2013;251:2555–2561
   PubMed Web of Science ®Google Scholar
• Gonzalez L, Loza RJ, Han KY, et al. Nanotechnology in corneal neovascularization therapy – a review. J Ocul Pharmacol Ther 2013;29:124–134
   PubMed Web of Science ®Google Scholar
• Rajappa M, Saxena P, Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem 2010;50:103–121
   PubMed Web of Science ®Google Scholar
• Keating AM, Jacobs DS. Anti-VEGF treatment of corneal neovascularization. Ocul Surf 2011;9:227–237
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 2014;4:64
   PubMedGoogle Scholar
• Vadlapatla RK, Vadlapudi AD, Mitra AK. Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets 2013;14:919–935
   PubMed Web of Science ®Google Scholar
• Hasskarl J. Everolimus. Recent Res Cancer 2014;201:373–392
   PubMedGoogle Scholar
• Kim S, Ding W, Zhang L, et al. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther 2014;7:719–728
   PubMed Web of Science ®Google Scholar
• Imbulgoda A, Heng DY, Kollmannsberger C. Sunitinib in the treatment of advanced solid tumors. Recent Res Cancer 2014;201:165–184
   PubMedGoogle Scholar
• Baspinar Y, Bertelmann E, Pleyer U, et al. Corneal permeation studies of everolimus microemulsion. J Ocul Pharmacol Ther 2008;24:399–402
   PubMed Web of Science ®Google Scholar
• Ko BY, Kim YS, Baek SG, et al. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model. Cornea 2013;32:689–695
   PubMed Web of Science ®Google Scholar
• Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985;4:531–535
   PubMed Web of Science ®Google Scholar
• Mehrjardi HZ, Ghaffari R, Mahbod M, Hashemi H. Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat model. J Ophthalmic Vis Res 2014;9:162–168
   PubMedGoogle Scholar
• Seo JW, Chung SH, Choi JS, Joo CK. Inhibition of corneal neovascularization in rats by systemic administration of sorafenib. Cornea 2012;31:907–912
   PubMed Web of Science ®Google Scholar
• Brocato J, Chervona Y, Costa M. Molecular responses to hypoxia-inducible factor 1α and beyond. Mol Pharmacol 2014;85:651–657
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Ocular neovascularization. J Mol Med 2013;91: 311–321
   PubMed Web of Science ®Google Scholar
• Patel JI, Tombran-Tink J, Hykin PG, et al. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res 2006;82:798–806
   PubMed Web of Science ®Google Scholar
• Krizova D, Vokrojova M, Liehneova K, Studeny P. Treatment of corneal neovascularization using anti-VEGF Bevacizumab. J Ophthalmol 2014;2014:178132. doi: 10.1155/2014/178132
   PubMed Web of Science ®Google Scholar
• Acar BT, Halili E, Acar S. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Int Ophthalmol 2013;33:507–513
   PubMed Web of Science ®Google Scholar
• Lichtinger A, Yeung SN, Kim P, et al. Corneal endothelial safety following subconjunctival and intrastromal injection of bevacizumab for corneal neovascularization. Int Ophthalmol 2014;34:597–601
   PubMed Web of Science ®Google Scholar
• Öner V, Küçükerdönmez C, Akova YA, et al. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model. Ophthalmic Res 2012;48:118–123
   PubMed Web of Science ®Google Scholar
• Kim J, Kim D, Kim ES, et al. Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovacularization. Int J Ophthalmol 2013;6:588–591
   PubMed Web of Science ®Google Scholar
• Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011;52:8718–8723
   PubMed Web of Science ®Google Scholar
• Kim EK, Kong SJ, Chung SK. Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits. Cornea 2014;33:60–64
   PubMed Web of Science ®Google Scholar
• Akar EE, Oner V, Küçükerdönmez C, Aydın Akova Y. Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model. Int J Ophthalmol 2013;6:136–140
   PubMed Web of Science ®Google Scholar
• Türkcü FM, Cinar Y, Türkcü G, et al. Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model. Cutan Ocul Toxicol 2014;33:138–144
   PubMed Web of Science ®Google Scholar
• Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007;10:141–148
   PubMedGoogle Scholar
• Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, et al. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010;150:519–528
   PubMed Web of Science ®Google Scholar
• Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, et al. Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model. Arch Soc Esp Oftalmol 2013;88:473–481
   PubMedGoogle Scholar
• Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011;4:51
   PubMed Web of Science ®Google Scholar
• Hennig M, Bauer D, Wasmuth S, et al. Everolimus improves experimental autoimmune uveoretinitis. Exp Eye Res 2012;105:43–52
   PubMed Web of Science ®Google Scholar
• Kim SH, Schmitt CE, Woolls MJ, et al. Vascular endothelial growth factor signaling regulates the segregation of artery and vein via ERK activity during vascular development. Biochem Biophys Res Commun 2013;430:1212–1216
   PubMed Web of Science ®Google Scholar
• Shin YJ, Hyon JY, Choi WS, et al. Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-β1/ERK pathways regulation. Invest Ophthalmol Vis Sci 2013;54:4452–4458
   PubMed Web of Science ®Google Scholar
• Zhong YY, Zhang HF, Zhong JX, et al. Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK1/2 and p38 pathways. Int J Ophthalmol 2011;4:150–155
   PubMed Web of Science ®Google Scholar